Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone by Ioannis Trigonis et al.
ORIGINAL ARTICLE
Early reduction in tumour [18F]fluorothymidine (FLT) uptake
in patients with non-small cell lung cancer (NSCLC) treated
with radiotherapy alone
Ioannis Trigonis & Pek Keng Koh & Ben Taylor & Mahbubunnabi Tamal & David Ryder &
Mark Earl & Jose Anton-Rodriguez & Kate Haslett & Helen Young & Corinne Faivre-Finn &
Fiona Blackhall & Alan Jackson & Marie-Claude Asselin
Received: 14 June 2013 /Accepted: 6 November 2013 /Published online: 7 February 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Purpose Changes in tumour 3′-deoxy-3′-[18F]fluorothymidine
(FLT) uptake during concurrent chemo-radiotherapy in patients
with non-small cell lung cancer (NSCLC) have been reported,
at variable time points, in two pilot positron emission tomog-
raphy (PET) studies. The aim of this study was to assess
whether FLT changes occur early in response to radiotherapy
(RT) without concurrent chemotherapy and whether such
changes exceed test-retest variability.
Methods Sixteen patients with NSCLC, scheduled to have
radical RT, underwent FLT PET once/twice at baseline to
assess reproducibility and/or after 5–11 RT fractions to
evaluate response. Primary and nodal malignant lesions were
manually delineated on CT and volume, mean and maximum
standardized uptake values (SUVmean and SUVmax) estimated.
Analysis included descriptive statistics and parameter fitting
to a mixed-effects model accounting for patients having dif-
ferent numbers of evaluable lesions.
Results In all, 35 FLT PET scans from 7 patients with a
total of 18 lesions and 12 patients with a total of 30
lesions were evaluated for reproducibility and response,
respectively. SUVmean reproducibility in primary tumours
(SD 8.9 %) was better than SUVmax reproducibility (SD
12.6 %). In nodes, SUVmean and SUVmax reproducibil-
ities (SD 18.0 and 17.2 %) were comparable but worse
than for primary tumours. After 5–11 RT fractions, pri-
mary tumour SUVmean decreased significantly by 25 %
(p=0.0001) in the absence of significant volumetric
change, whereas metastatic nodes decreased in volume
by 31 % (p=0.020) with a larger SUVmean decrease of
40 % (p<0.0001). Similar changes were found for
SUVmax.
Conclusion Across this group of NSCLC patients, RT
induced an early, significant decrease in lesion FLT up-
take exceeding test-retest variability. This effect is vari-
able between patients, appears distinct between primary
and metastatic nodal lesions, and in primary tumours is
lower than previously reported for concurrent chemo-RT
at a similar time point. These results confirm the poten-
tial for FLT PET to report early on radiation response
and to enhance the clinical development of novel drug-
radiation combinations by providing an interpretable,
early pharmacodynamic end point.
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Introduction
Lung cancer is the most common cause of cancer-related
mortality worldwide [1]. Radiotherapy (RT) plays a major
therapeutic role in patients with non-small cell lung cancer
(NSCLC). RT is given with radical intent in patients with
early-stage disease who are medically unfit for resection and
in locally advanced inoperable disease [2]. Patients with lo-
cally advanced (stage III) NSCLC are generally treated with a
combination of chemotherapy and RT delivered sequentially
or concurrently [3]. Although concurrent chemo-RT has been
shown to be associated with improved outcomes this is at a
cost of added toxicity and utilized in empirically selected
patients, underlining the need for robust efficacy and toxicity
biomarkers in both approaches [4].
Further improvements in outcome will require the use of
minimally invasive response biomarkers in two distinct but
interdependent settings: Firstly, in the preclinical and early-
phase clinical trial setting where the inclusion of surrogate
pharmacodynamic end points, measured at the population
level, may facilitate the rational selection and optimization
of novel RT-based regimens [5, 6] and secondly, in late-phase
clinical trials and, potentially, in routine clinical practice
where response stratification across individual subjects and/
or lesions may enable spatially and/or temporally adaptive
radiotherapeutic approaches [7, 8]. As a prerequisite step
further technical validation and qualification of candidate
biomarkers is required [9].
Intrinsic radiosensitivity and tumour repopulation are
(along with cell repair, re-oxygenation and cell cycle r-
edistribution) two of the five “R’s” determining RT efficacy
according to classical radiobiology [10]. As both are intimate-
ly linked to changes of tumour proliferation, it is reasonable to
hypothesize that monitoring changes of tumour proliferation
during RTmay provide surrogate information on response and
patient outcome.
3′-deoxy-3′-[18F]Fluorothymidine (FLT) positron emission
tomography (PET) allows non-invasive evaluation of tumour
proliferation. FLT uptake primarily depends on phosphoryla-
tion mediated by thymidine kinase 1 (TK1). TK1 is up-
regulated 10- to 20-fold during S phase; therefore, FLT uptake
parameters provide a surrogate measurement for S-phase frac-
tion and proliferation rate [11]. Validation studies have dem-
onstrated significant correlations between baseline lung tu-
mour FLT uptake parameters and the proliferation index Ki-
67 [12–16].
In xenograft models, irradiation induced early de-
creases of tumour FLT uptake, generally preceding
[18F]fluorodeoxyglucose (FDG) changes [17–20]. Two pilot
studies have reported changes of tumour FLT uptake at vari-
able time points during the course of concurrent/sequential
chemo-RT, each including five patients with NSCLC [21, 22].
In the two patients who were studied after 2 days of treatment,
primary tumour maximum standardized uptake value
(SUVmax) exhibited changes of +22 and −27 %. After 8 days
larger decreases of 39 and 40%weremeasured in two patients
[21]. The remaining patients were studied in the fifth week of
treatment and large variable decreases were reported in pri-
mary tumour SUVmax, ranging from 25 to 71 %, after 44–
48 Gy [22]. Although the first study reported “a disparity in
the anatomical and metabolic response of primary tumour and
lymph nodes” [21], no statistically significant differences
were found in FLT responses between the two lesion types
in the second [22]. As most patients studied received concur-
rent chemo-RT, the relative contribution of the two treatment
components to the observed changes is unclear. To date there
are no data available relating to FLT uptake changes in re-
sponse to RT alone.
We conducted a prospective study aiming to investigate the
magnitude, significance and variability of tumour FLT uptake
changes after 1–2 weeks of radical RT without concurrent
chemotherapy. This work was performed as a sub-study of
RADAR (Radiation Damage And Resistance in lung cancer),
aManchester LungCancer Groupmultimodality study aiming
to discover, evaluate and validate novel blood and imaging
biomarkers of RT response and toxicity in lung cancer.
Materials and methods
Patients
We recruited patients with a histological or cytological diag-
nosis of NSCLC scheduled to receive radical RT as per stan-
dard of care. Patients who had received induction chemother-
apy prior to RTwere eligible; however, those planned to have
concurrent chemo-RTwere excluded. Other eligibility criteria
included Eastern Cooperative Oncology Group (ECOG) per-
formance status 0 or 1, presence of a primary tumour exceed-
ing 2 cm inmaximum diameter and written, informed consent.
In women of childbearing potential, pregnancy was excluded
by measurement of urine beta human chorionic gonadotropin
(β-HCG). The study protocol was approved by the local
Research Ethics Committee (REC, 09/H1011/55) and Admin-
istration of Radioactive Substances Advisory Committees
(ARSAC, 595-3742/25138) and has therefore been performed
in accordance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments.
Patients were treated on a linear accelerator using 6-MV
photons with a total dose of 50–55 Gy in 20 once-daily
fractions or 60–66 Gy in 30–33 fractions. Consenting pa-
tients underwent one or two (optional) baseline FLT
PET/CT scans (Scan1/Scan2) followed by a further scan
during the second week of treatment (Scan3). Therefore,
patients were evaluable for either baseline reproducibility
of FLT PET parameters, RT response or both.
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The individual time intervals between scans and treatments
are tabulated in Table 1. Patients who had received induction
chemotherapy underwent the first baseline scan 11–49 days
(median 26 days) after the last cycle. In reproducibility-
evaluable patients, baseline scans were performed within 2–
6 days (median 4.0 days) of each other. In response-evaluable
patients, RT was initiated 1–13 days after the latest/single
baseline scan (median 5.0 days). Response assessment scans
were performed after 6–15 calendar days on treatment (medi-
an 8.5 days), corresponding to 5–11 RT fractions (median 7.5
fractions).
Clinical follow-up included medical history and physical
examination 1, 3 and 6 months following completion of RT
and subsequently as per local practice. Imaging follow-up
included contrast-enhanced CT of thorax and abdomen at
4 weeks, 6 months and 12 months following completion of
RT and subsequently as required at the discretion of the
treating physician. Overall survival (OS) was defined as time
from RT initiation to death, irrespective of cause.
Locoregional control (LRC) was defined as time from RT
initiation to local disease progression according to RECIST
1.1 criteria [23]. For patients that are still alive and/or local
progression had not been detected at the time of death, LRC
and OS were calculated relative to the date of last follow-up.
PET data acquisition
FLT was either synthesized in-house as described in [24] or
externally supplied (PETNET Solutions Inc., Nottingham,
UK or Wolfson Brain Imaging Centre, University of Cam-
bridge, Cambridge, UK).
All PET scans were performed at the Wolfson Molecular
Imaging Centre (WMIC,Manchester, UK) using the Biograph
6 Truepoint TrueV scanner (Siemens Molecular Imaging Inc.,
Knoxville, TN, USA). This is a four-ring lutetium
oxyorthosilicate (LSO)-based 3D PET scanner with an axial
field of view (FOV) of 21.6 cm coupled with a six-slice helical
CTscanner. FLTwas injected as a 30-s bolus of 254–361MBq
(mean 311 MBq), and each emission scan was performed at a
single bed position without respiratory gating. The PET scan
was followed by a non-breath-hold, non-contrast-enhanced
CT scan according to manufacturer recommendations (peak
energy 130 keV, 70 mAs). CT data were reconstructed at high
and low spatial resolutions for volumes of interest (VOI)
delineation and for attenuation and scatter correction pur-
poses, respectively. PET data acquired 45–60 min post-
injection were reconstructed as a single frame using 3D
ordered subset expectation maximization (OSEM) with 4
iterations and 21 subsets to a 256×256×109 matrix,
corresponding to voxel size of 2.67×2.67×2.00 mm3.
PET images were smoothed using a 3D 4-mm Gaussian
filter post-reconstruction.
Image analysis
PET images were decay-corrected and normalized for injected
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Primary tumours and metastatic lymph nodes were man-
ually delineated slice by slice transaxially by an experi-
enced oncological radiologist (B.T.) to generate 3D
VOIs on the baseline and response scans using Analyze
image analysis software (Biomedical Imaging Resource,
Mayo Foundation, Rochester, MN, USA). Lesion delinea-
tion aimed to include entire malignant lesions as whole,
potentially heterogeneous anatomical entities and was not
limited to FLT-avid areas. Hence VOI delineation was
primarily CT-based and co-registered PET images were
only considered as required, for example to aid in the
delineation of tumour from consolidated lung or to more
accurately determine the margins of masses which abutted
the mediastinum. Standardized CT window settings were
used to delineate tumour from adjacent lung (lung win-
dows; level −500 HU, width 1,500 HU) or from adjacent
soft tissues (soft tissue windows; level 0 HU, width 400
HU). A fixed visualization window between 0 and 4 was
used for the smoothed SUV maps. Enlarged mediastinal
nodes or nodes of normal size showing increased FLT
uptake were included in the analysis and delineated on CT
with soft tissue windows. Representative CT and PET SUV
images of patient 11 are shown in Fig. 1 at baseline and
after 10 RT fractions. Contamination of tumour VOIs by
normal proliferating bone marrow signal may cause sub-
stantial errors such that in tumours adjacent to the skeleton
particular care was taken to ensure a margin between the
delineated VOI and bone. The quality of PET/CT co-
registration, which can be compromised by patient move-
ment, was visually assessed and VOIs were manually ad-
justed as required.
Statistical analysis
For each evaluable VOI (primary tumour or metastatic lymph
node), three parameters were extracted: volume in cm3,
SUVmean and SUVmax. Individual test-retest difference and
RT-induced response were calculated using Eqs. 2 and 3,
respectively:
Test−retest difference %ð Þ ¼ Scan2−Scan1
Scan1þ Scan2  200 ð2Þ
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Table 1 Patient (Pt) characteristics. TNM tumour, node, metastasis
staging, AdenoCa adenocarcinoma, LUL left upper lobe, RLL right
lower lobe, RML right middle lobe, LLL left lower lobe, RUL
right upper lobe,PRpartial response, SDstable disease, BEDbiologically
effective dose, na, non-applicable, Cis cisplatin, Pem pemetrexed, Carbo
carboplatin, Gem gemcitabine. Reproducibility-evaluable patients are
highlighted in grey and response-evaluable patients are encompassed
within red border
a International Association for the Study of Lung Cancer lymph node map (2009). b / indicates drug switch, - denotes drug combination and x precedes
number of chemotherapy cycles. c Date of last chemotherapy administration. d All patients in the response cohort were treated with a total dose of 50-
55 Gy in 20 once-daily fractions except one patient (13) who was given 66 Gy in 33 fractions.
Fig. 1 Representative CT (left)
and PET (right, SUV 45–60 min)
images of patient 11 acquired at
baseline (top) and after delivery of
27.5 Gy (bottom). Primary tumour
is manually delineated within
green outline. Note sharply
demarcated dramatic reduction in
bone marrow uptake and modest
reduction of tumour uptake after
RT, as previously reported [21]
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Response %ð Þ ¼ Scan3−Baseline
Baseline
 100 ð3Þ
where Baseline is the latest/single baseline parameter value for
Scan1or Scan2. Reproducibility was estimated as the standard
deviation (SD) of the mean test-retest differences across pa-
tients and as the average of the absolute test-retest differences
across patients (absolute reproducibility).
To allow comparison of the effects of different fraction-
ation regimens, we calculated the biologically effective dose
(BED) at the time of the response scan (Scan3) using Eq. 4:





where n is the number of RT fractions, D (in Gy) is the
administered dose per fraction and α/βwas set to 10 for both
primary and nodal lesions [25].
Descriptive statistics
Descriptive summary statistics of the difference between
Scan1 and Scan2 for each parameter including mean and SD
were calculated. The repeatability coefficient (RC=1.96×SD)
was also calculated to support comparison with previously
published reproducibility values for FLT [26, 27]. Differences
between lesion volume and SUV before and during RT were
tested using theWilcoxon rank sum test. Potential correlations
amongst baseline parameters and between baseline parameter
values and reproducibility values were assessed using
Spearman’s rho coefficient test (two-sided). No correction
for multiple testing was used in this exploratory analysis.
Mixed-effects models
As most patients had more than one evaluable lesion, the
SUVmean, SUVmax and volume values, transformed to a com-
mon (base 10) logarithmic scale for the purpose of this anal-
ysis, were each fitted separately to two linear mixed-effects
models using analysis of covariance (ANCOVA): The first
model (A) pertains to the reproducibility-evaluable patients
and was implemented on the duplicate baseline values with
the Scan2 value representing the dependent variable. Covari-
ates included the Scan1 value and type of lesion (primary vs
node) as fixed-effect terms. The second model pertains to the
response-evaluable patients and was implemented with the
Scan3 value representing the dependent variable. Covariates
included the latter/single baseline value (Scan1/2) and type of
lesion (primary vs node) as fixed-effect terms. BED was also
assessed as an additional covariate. To account for patients
having more than one evaluable lesion, a random effect term
was included in both models to account for potential nested
effects within patients, i.e. heterogeneity across patients. The
models are described in more details with the results presented
in Table 3.
Analysis of outcome data
Median times for LRC and OS were calculated using the
Kaplan-Meier method. Potential associations of both outcome
end points with primary tumour continuous PET parameters
(baseline, on-RT and response values for SUVmean and
SUVmax) were investigated using univariate Cox regression
without correction for multiple testing.
Statistical tests were performed using SPSS version 19
(SPSS Inc., Chicago, IL, USA) or the statistical software R.
A p value below 5 % was considered to be statistically
significant.
Results
Between June 2010 and August 2012, 19 patients were re-
cruited into the study. Three patients withdrew after the first
baseline scan and were therefore not evaluable. Of the remain-
ing 16 patients, 3 underwent 2 baseline and 1 on-treatment
scans and were evaluable for both reproducibility and re-
sponse. Four patients underwent two baseline scans and were
evaluable for reproducibility only. Nine patients underwent a
single baseline and an on-treatment scan and were evaluable
for response only. Overall, 7 patients with a total of 7 primary
and 11 lymph node lesions were evaluable for reproducibility
and 12 patients with a total of 12 primary and 18 lymph node
lesions were evaluable for response.
Clinical characteristics of evaluable patients and informa-
tion on the timing of FLT PET scans are summarized in
Table 1. Most subjects had stage III disease (13 of 16) and
most (13 of 16) received induction chemotherapy; of the latter,
the majority (11 of 13) demonstrated partial response to treat-
ment. Baseline volume, SUVmean and SUVmax of all evaluable
lesions are shown in Fig. 2. Respective summary statistics of
baseline, reproducibility and response values for primary tu-
mours and lymph nodes from the PET/CT images are given in
Table 2. The primary tumour volumes were significantly
larger (5.0–210.7 cm3) than nodal volumes (1.3–21.4 cm3)
at baseline (p<0.001). Review of lesion SUVs reveals sub-
stantial variability of baseline uptake between patients, e.g.
primary tumour SUVmean ranged from 0.9 to 3.4 with similar
variability observed in nodes (0.9–3.1). In several cases, sub-
stantial uptake differences were observed within subject: In
13/16, subjects’ primary tumour uptake was higher than or
similar to that of metastatic nodes, whereas in 3 subjects
(patients 2, 10 and 16), nodal uptake was greater than the
primary tumour.
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Across all lesions, there was a strong significant correlation
between baseline SUVmax and SUVmean (Spearman’s rho
0.91, p<0.001) and a modest but also significant correlation
between SUVmax and volume (rho 0.58, p<0.001), whereas a
weak significant correlation was found between SUVmean and
volume (rho 0.36, p=0.020). When primary tumours were
examined separately from nodes, SUVmax correlated signifi-
cantly with SUVmean for both lesion types (primary tumours
rho 0.93, p<0.001; nodes rho 0.92, p<0.001). Likewise,
SUVmax correlated significantly with volume (primary tu-
mours rho 0.59, p=0.016; nodes rho 0.53, p=0.006), but
SUVmean correlated significantly with volume only for the
nodes (primary tumours rho 0.35, p=0.19; nodes rho 0.46,
p=0.020).
Reproducibility of individual patients is plotted in relation
to baseline values in Fig. 3a. Across all lesions, the absolute
SUV test-retest differences did not correlate with average
baseline lesion SUVmax (rho −0.10, p=0.70) or SUVmean
(rho −0.10, p=0.69). In contrast, we found a significant neg-
ative correlation between absolute volume test-retest differ-
ences and average lesion volume (rho −0.57, p=0.015). Ac-
cordingly, primary tumour volume reproducibility (SD 12.8)
was substantially better compared to nodal lesions (SD 22.5).
Consequently, volume RCs were estimated separately for
these lesion types, whilst the SUV RC was estimated jointly
for primary tumour and nodal lesions and was similar for
SUVmean (SD 14.9 %) and SUVmax (SD 15.3 %).
RT response of individual patients is similarly plotted
against baseline values in Fig. 3b. RT-related primary tumour
volume changes ranged from −33.9 to+33.1 % (mean change
+6 %, p=0.84). In most (9/12) cases, these changes did not
exceed the RC (25 %). On the other hand, metastatic node

























Fig. 2 Baseline (single/average)
volume (top), SUVmean (middle)
and SUVmax (bottom) of primary
tumours (squares) and metastatic
nodal lesions (circles) of 16
patients
Table 2 Summary statistics of lesion imaging parameters (SUVmean,
SUVmax and volume) with reproducibility and response 1–2 weeks after
RT initiation. Values are presented as mean±SD. For the reproducibility
cohort, 7 primaries and 11 nodes are averaged. For the response cohort,
12 primaries and 18 nodes are averaged
Lesion Reproducibility cohort Response cohort Test-retest differences (%)b Responses (%)
1st baseline values 2nd baseline values Baseline valuesa Response values
Volume (cm3)
Primaries 38±31 40±31 78±56 85±63 9.5±12.8 (9.8) 6.0±19.1
Nodes 7.5±4.0 8.6±6.3 7.4±5.3 5.9±5.5 8.4±22.5 (19.3) −16.9±57.0
All 19±24 21±25 36±49 38±56 8.8±18.9 (15.6) −7.7±46.7
SUVmean
Primaries 1.6±0.7 1.6±0.6 2.2±0.7 1.6±0.4 −2.9±8.9 (6.8) −24.3±13.9
Nodes 2.1±0.5 2.2±0.7 1.7±0.4 1.1±0.4 0.6±18.0 (11.9) −39.7±14.6
All 1.9±0.6 1.9±0.7 1.9±0.6 1.3±0.5 −0.8±14.9 (9.9) −33.5±16.0
SUVmax
Primaries 3.5±1.7 3.6±1.5 5.3±2.0 4.1±1.4 5.7±12.6 (9.5) −22.9±13.6
Nodes 4.0±1.3 4.3±1.9 3.2±0.9 1.8±0.7 3.1±17.2 (14.0) −44.4±15.9
All 3.8±1.5 4.1±1.8 4.1±1.7 2.7±1.5 4.1±15.3 (12.3) −35.8±18.2
a The second baseline scan was used for patients with two baseline scans
b Reproducibility given by the SD of the mean test-retest differences. Average of the individual absolute test-retest differences added in parentheses.
Both estimates and mean responses highlighted in bold
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volume changes ranged from −90.0% to an outlier increase of
+170.4 %, demonstrating a decrease exceeding the RC (44 %)
in 5/18 lesions from 3/12 patients. RT-induced changes of
lesion SUVs ranged from −54.9 to +7.6 % for SUVmean and
from −62.0 to +1.6 % for SUVmax. Examined separately,
nodes demonstrated a 40±15 % decrease in SUVmean that on
average was 1.6 times higher than the 24±14 % decrease of
primary tumours (1.9-fold for SUVmax). SUVmean response
correlated strongly with SUVmax response (rho 0.89,
p<0.0001).
Malignant lesion SUVmax during RT (normalized to
single/latest baseline value) is plotted against calendar
days on RT in Fig. 4, as previously presented by Everitt
et al. [21]. During the course of our response assessment
window, no significant dose-response relationship was
found between SUVmax response in primary tumours
and days since start of RT (rho=0.27, p=0.39), nor with
RT dose delivered or BED.
The results of the ANCOVA are outlined in Table 3. The
mixed-effects model implemented on the reproducibility
data set (model A) did not provide any evidence of a
systematic effect (progression/decline) of the retest values
in relation to the test values for any of the parameters
SUVmax, SUVmean or volume for either primaries or nodes.
The fit of the response data to model B did not improve by
adding BED as a covariate for any of the parameters
SUVmax, SUVmean or volume. Therefore, BED was not
included in the final implementation of model B. On aver-
age, the model estimated a significant decrease in SUVmean
of 25 % [confidence interval (CI) −15 to −34 %] in the
primary lesions post-RT. Furthermore, the treatment effect
for nodes was significantly different to primaries (p=
0.004), with a larger 40 % (CI −33 to −46 %) decrease.
Similarly, the model estimated a significant RT-related de-
crease of primary tumour SUVmax by an average of 24 %
(CI −13 to −34 %), which was significantly lower (p=
0.0006) compared to the average 46 % (CI −39 to −52 %)
decrease in SUVmax for nodes.
With regard to lesion volume, primary tumours demon-
strated no significant change (4 %, CI −27 to +48 %, p=0.81)
in response to treatment. In contrast, the model estimated an
average decrease of 31 % (CI −6 to −49 %) in node volume
that was significant (p=0.020) and significantly different to
primary tumours (p=0.060).














































































Fig. 3 a Lesion reproducibilities
(%) plotted against mean baseline
lesion values for volumes (top),
SUVmean (middle) and SUVmax
(bottom). bRT-induced responses
(%) plotted against baseline
parameter values (second baseline
scan if two baseline scans
acquired). Dashed lines in SUV
graphs set at mean test-retest
difference ± RC=1.96×SD,
where SD is standard deviation of
respective parameter
reproducibility. In volume graphs
dashed lines not displayed as
absolute volume reproducibility
correlated with baseline average
volume. Primary tumours
represented by squares and
metastatic nodes by circles. The
second evaluable lesion of patient
7 (4R) was measured as 170 %
larger post-RT. This outlier is not
shown in b, to enhance visibility,
nevertheless was included in the
statistical analyses
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For all three parameters, the random variation across pa-
tients estimated by model B was small compared to the
variation across lesions. For SUVmean, the cross-patient
(nested) effect accounted for about 28.7 % of the total vari-
ance. The contribution of cross-patient variance to the total
variance was even smaller for SUVmax and volume at 15.5 and
13.3 %, respectively. One year after recruiting the last patient
(September 2013), the median follow-up time was
15.4 months after RT initiation (range 3–33 months). At that
time point, 9 patients had documented local primary tumour
progression, 5 had developed metastatic disease and 11 had
died of which 1 (patient 2) before treatment completion.
Median LRC and OS times were 12.2 (CI 6–18) and 19.5
(CI 9–30) months, respectively. Cox regression analysis iden-
tified no significant association between OS and baseline, on-
RT or response values of primary tumour SUVmean and
SUVmax (p>0.08). However, LRC was found to be associated
with primary tumour SUVmax on-RT (hazard ratio 2.31, CI
1.06–5.00, p=0.034) but not with SUVmax at baseline (hazard
ratio 1.46, CI 0.97–2.18, p=0.068) or SUVmean on RT (hazard
ratio 5.80, CI 0.66–50.6, p=0.112). This exploratory analysis
is graphically presented for LRC in Supplementary Fig. 1.




























Fig. 4 Lack of dose-response
relationship between SUVmax
response (expressed as ratio of
SUVmax during RT to single/latest
baseline value) and calendar days
on RT. Primary tumours
represented by squares and
metastatic nodes by circles
Table 3 Tabulated results of ANCOVA performed separately for lesion
SUVmean, SUVmax and volume at duplicate baseline scans (model A) and
in response to RT (model B). The linear mixed-effects model was gener-
ally formulated as log10(y1ij)=log10(y0ij)+(β0+bi)+β1x1ij+εij. In model A,
y0ij is the initial baseline and y1ij is the second baseline value for patient i
and lesion j, whereas in model B, y0ij is the pre-RT value and y1ij is the
post-RT value for patient i and lesion j. In both models, x1 indicates the
type of lesion (set to 0 if primary or 1 if node) such that β0 is the ‘intercept’
for primaries and β0+β1 is the intercept for nodes. In both models, bi∼
N(0, σb
2) represents the cross-patient heterogeneity random term (σb
2 is the
variance across patients) and εij∼N(0, σ2) represents the model error that
is due to variability across lesions and ‘pure’ model error (σ2 is the
residual error variance). Note that parameter estimates are based on log-
transformed data and hence need to be back-transformed to allow esti-
mation of effect size. For example, the model-estimatedmean RT-induced
SUVmean effect size ratio can be calculated from β0,β1 values frommodel
y1=y0−1 ¼ 10 β0þβ1ð Þ−1 for nodes. The proportion of the variation in the
intercept that is accounted for by patient heterogeneity can be calculated
as σb
2/(σ2+σb
2). The Akaike Information Criterion (AIC) provides a mea-
sure of the goodness of the fit to the four-parameter ( β0;β1;σb2 ;σ2
 
models
Model A (reproducibility) parameters SUVmean SUVmax Volume
Fixed effectsa β0
b −0.014±0.025 (0.60) 0.024±0.026 (0.37) 0.041±0.031 (0.11)
β1
c 0.015±0.032 (0.65) −0.025±0.027 (0.38) −0.025±0.031 (0.43)
Random effects σb
2 0.00000 0.00188 0.00300
σ2 0.00448 0.00291 0.00374
AIC −28.78 −30.20 −25.42
Model B (response) parameters SUVmean SUVmax Volume
Fixed effectsa β0
b −0.127±0.025 (0.0001) −0.119±0.029 (0.0007) 0.018±0.073 (0.81)
β1
c −0.095±0.029 (0.004) −0.147±0.035 (0.0006) −0.177±0.089 (0.06)
Random effects σb
2 0.00224 0.00154 0.00858
σ2 0.00556 0.00839 0.05579
AIC −45.24 −37.02 15.46
aModel parameters for fixed effects presented as estimate ±standard error (p value)
b p values from statistical comparison against 0
c p values from statistical comparison against primary tumours
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Discussion
We have confirmed previous studies on FLT parameter repro-
ducibility and demonstrated that, in patients with NSCLC, RT
induces an early, significant decrease in tumour FLT uptake
which is lower than previously reported for concurrent
chemo-RT at a similar time point [21]. After 1–2 weeks of
RT, the magnitude of this response was found not to be driven
by variations in the RT dose delivered but to vary between
primary tumours and metastatic nodal lesions, possibly indi-
cating distinct intrinsic radiosensitivities. This contrasts with
the previously reported findings that FLT response did not to
differ between lesion types after 5–6 weeks of chemo-RT and
depended on the RT dose received [22].
Establishing the effect of treatment on a potential imaging
biomarker is best performed in the context of validating its
precision. Therefore, we performed a combined assessment of
tumour FLT PET parameter reproducibility and response. To
date, three groups have reported on the reproducibility of
tumour FLT SUVs in patients with lung and other cancers
[28–30], while two further publications addressed the issue of
metabolic volume reproducibility [26, 27]. In all cases, tu-
mour VOIs were delineated on PET images, either manually
or using semi-automatic segmentation methods. In contrast, in
our study, tumour VOIs were delineated primarily on anatom-
ical CT images, aiming to capture the mean uptake across both
avid and less avid tumour regions. Furthermore, previous
studies largely included treatment-naive subjects, whereas
most patients enrolled in our study had received induction
chemotherapy before acquisition of the baseline scans. Con-
sequently, average lesion SUVmean in our subjects was sub-
stantially lower than in previous studies (SUVmean∼2 com-
pared to more than 3). Despite such differences, SUVmean
reproducibility results across studies were comparable: Repro-
ducibility in our study was 14.9 % (primaries 8.9 %, nodes
18.0 %) compared to 10.5 % [28], 7.0 % [29] and 4.5 % [30]
in previous reports exclusively or predominantly including
primary lesions. Despite the use of image smoothing and
absence of variability associated with VOI delineation, prima-
ry tumour SUVmax was less reproducible (SD 12.6 %) than
SUVmean. These results are in agreement with the main con-
clusion of a recent meta-analysis of FDG studies demonstrat-
ing SUVmean as the most reproducible SUV parameter [31].
This superiority was lost in nodal lesions for which SUVmax
was marginally more reproducible than SUVmean.
In terms of volume reproducibility, we found that manual
delineation of malignant NSCLC lesions by a single imaging
expert yielded VOIs with volumetric precision at least equiv-
alent to semi-automatic segmentationmethods including fixed
threshold, adaptive threshold or cluster-based methods imple-
mented in two previous publications in patients with lung and
breast cancer [26, 27]. However, it is expected that manual
tumour delineation, unlike semi-automatic methods, will
suffer from additional inter-observer variability [32]. In accor-
dance with previous reports, we found that the volume repro-
ducibility of manually delineated lesions correlated negatively
with their size [26, 27]. Therefore, using the same confidence
intervals across a wide spectrum of volumes is inappropriate.
Optimal volumetric response assessment would require one or
more cut-off values defined through analysis of a large repro-
ducibility data set and/or simulation studies.
Taken together, this and other recent reports indicate that,
in lung cancer, FLT SUV parameters are similarly robust to
respective FDG parameters, with only a modest impact from
the segmentation approach used. Changes of primary tumour
SUVmean exceeding 17 % and SUVmax exceeding 25 % are
likely to be significant. Lesion volume, delineated manually
on PET/CT images or with semi-automatic PET-based seg-
mentation methods is generally a less precise parameter, es-
pecially for small lesions.
When we designed this study, we considered the choice of
potential time points to assess response. Based on preclinical
reports [17–20] and the first pilot clinical study [21], we
elected an early assessment point aiming to obtain an early
read-out of intrinsic radiosensitivity and minimize the con-
founding effect of volumetric changes and potential RT-
related inflammatory changes on tumour uptake. Furthermore,
to limit the variability of RT dose delivered at the time of on-
treatment scans, while maintaining study feasibility, we re-
stricted the response assessment window to 1 week.
We found that in the absence of significant changes in
average primary tumour size, RT induced a significant de-
crease of about 25 % in FLT uptake after a week of treatment,
as measured by both SUVmean and SUVmax. In contrast,
metastatic nodes sustained a significant decrease in mean
volume associated with a decrease in FLT uptake significantly
exceeding that observed in primary tumours. Considering that
primary tumours routinely receive RT doses at least equivalent
to metastatic nodes, the observed difference in uptake re-
sponse may be attributed to genuine differences in biological
behaviour between primary and metastatic nodal lesions in
terms of perfusion, FLT-specific transport and/or phosphory-
lation in response to treatment. These processes cannot be
separated by simple SUV measurements. Alternatively, the
RT dose delivered to the metastatic nodes may differ from that
to the primary tumour. Finally, considering the potential inter-
action of size and uptake, which may be enhanced in small/
shrinking lesions, it is possible that the observed decreases of
the size of some nodal lesions may have contributed to an
artefactual decrease of measured uptake. On a different but
relevant note, response results will differ on whether absolute
or percentage differences are calculated. Considering that in
most response-evaluable patients baseline primary tumour
uptake exceeded that of metastatic nodes, an absolute differ-
ence response assessment would attenuate differences in re-
sponse between primaries and nodes.
690 Eur J Nucl Med Mol Imaging (2014) 41:682–693
In addition to differences between primaries and nodes, we
observed variable changes in FLTuptake across all lesions and
across primaries and nodes separately. This is complicated
further by the fact that different patients had variable numbers
of evaluable lesions. To disentangle these interactions, we
used a mixed-effects linear model. The statistical outcome
suggests that the response variability across patients (i.e. a
nested effect) had a limited contribution to the overall vari-
ability, which was mainly driven by lesion-to-lesion differ-
ences. In other words, response heterogeneity was most prom-
inent across lesions rather than across patients. Variations in
the RT dose delivered over the course of a week did not
explain the variability in FLT responses in the early phase of
treatment. Considering the spectrum of baseline variability
and treatment-related changes illustrated in Fig. 3, this point
in the course of RT SUVanalysis may support early response
stratification of lesions into responding and not responding.
Two previous studies have reported treatment-related FLT
SUVmax changes, each in five patients each receiving concur-
rent chemo-RT. Everitt et al. were first to assess patients with
NSCLC at variable time points ranging from 2 to 29 days of
treatment [21]. After 10 Gy, primary tumour SUVmax reduced
by 40 % in two cases, while in two subjects 20 Gy induced
decreases exceeding 60 %, as compared to an average de-
crease of 24 % after 12–30 Gy in our study. These differences
may to some extent reflect the added effect of concurrent
chemotherapy. Vera et al. studied NSCLC patients using
FLT, FDG and [18F]fluoromisonidazole (FMISO for hypoxia)
PET at baseline and after 4–5 weeks of radical concurrent/
sequential chemo-RT [22]. The decrease in FLT SUVmax at
this later time point was 46±21 % in primary tumours, com-
parable to that previously reported by Everitt et al. [21] and
appeared lower and more variable (29±60 %) in mediastinal
lymph nodes; nevertheless, no significant differences between
primaries and nodes were found. In contrast to our results, and
despite a narrower response assessment window (44–58 vs
12–30 Gy), they interestingly found that one third of the
variations in FLT responses could be accounted by the dose-
response relationship when considering tumours and nodes
together and adjusting for inter-patient heterogeneity, possibly
indicating that during the latter phase of treatment tumour
uptake may be undergoing more dynamic changes. Neither
lesion volumes nor changes in volume which could have
confounded the changes in FLT uptake, especially in the later
phase of treatment, were reported in this study.
Similarly to previous investigators [21], we observed a
dramatic reduction in FLT uptake of normal bone marrow
within the RT field. In this study, at least half of evaluable
primary tumours and/or metastatic nodal lesions were adjacent
or proximal to proliferating bone. It is worth noting that in
such cases there is a risk for incorrect response assessment,
which is exacerbated for RT compared to chemotherapy. For
example, erroneous inclusion of a segment of proliferating
bone marrow within the tumour VOI at baseline may lead to
response overestimation. Such a risk may be higher in the
absence of co-registered CT, or in cases of PET/CT mis-
registration, and can have major effect on study results, in
particular when SUVmax is used to assess response.We tried to
minimize this risk by comprehensive co-registration assess-
ment and exclusion of any overlap of the skeleton with tumour
VOIs.
Compared to the concurrent approach, sequential chemo-
RT lends itself to the separate study of systemic and local
treatment on tumour response. Nevertheless, recent chemo-
therapy could still have influenced the changes observed on-
RT by either affecting the baseline tumour proliferative status
or through a persistent pharmacodynamic effect especially in
the early course of RT. Although the interval between chemo-
therapy completion and baseline imaging in response-
evaluable subjects was at least 2 weeks and duplicate baseline
scans up to a week apart did not detect significant changes in
tumour size or proliferative activity, induction chemotherapy
could have confounded changes in tumour FLT uptake attrib-
uted to RT to a degree not quantifiable in this data set.
Although survival analysis was not a primary objective of
this study, we explored potential relationships of primary
tumour SUV parameters, at baseline, during treatment and
their relative change, with tumour control and patient out-
come. Instead of defining arbitrary cut-off point(s) that would
split the small sample size into smaller subgroups sensitive to
the cut-off point(s) selected, we followed a univariate regres-
sion approach. Our results indicate a possible association of
primary tumour SUVmax, but not SUVmean, after 1–2 weeks of
RT and eventual LRC. On the other hand, OS, potentially
influenced by multiple variables in addition to local control,
was not significantly associated with any local tumour imag-
ing parameter. This interesting finding should be interpreted
with caution because of the lack of detection power and the
risk of type I error associated with multiple testing on a small
sample size, which was further reduced by censoring. How-
ever, it could serve as an a priori hypothesis to be formally
tested by a larger subsequent study, ideally with pre-planned
multivariate analysis to account for additional clinical and
imaging parameters.
Despite a larger number of patients compared to earlier
work, our study was still limited in size. In our experience,
patient recruitment in this setting can be challenging. Lung
cancer patients are often symptomatic, frail or elderly and
participation in a molecular imaging study is associated with
the burden of additional scans without a potential therapeutic
benefit. Comprehensive evaluation of FLT PET in this setting
would require recruitment of large numbers of patients to be
evaluated at various time points, in order to elucidate both the
time course and heterogeneity of responses and repopulation.
The logistic limitations related to accomplishing such a pro-
ject in a single centre raise the importance of standardizing
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methodology and multi-centre collaborations, more easily
achieved using SUV than kinetic analysis. A further limitation
of our work arises from the lack of some form of respiratory
motion correction. Respiratory motion and to a lesser extent
partial volume effects are expected to induce an interaction
between size and SUV, resulting in bias especially in small
peripheral lesions [33, 34].
In summary, this is the first study demonstrating that RT, as
single treatment modality, induces in a subgroup of patients an
early, significant decrease of primary lung tumour FLT uptake
in the absence of significant mean volumetric changes. Met-
astatic nodes follow a discrete pattern of change with some
early volumetric regression and a larger decrease in FLT
uptake. These results confirm the potential for FLT PET to
report early on radiation response and to enhance the clinical
development of novel drug-radiation combinations by provid-
ing an interpretable, early pharmacodynamic end point. The
variability of responses observed indicates some potential for
patient stratification in future clinical trials evaluating RT.
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